Scope
Reference
CM_PHR_25_5731
Description
NHS Branded Medicines Tranche B - Lot 1 - London & South of England - CM/PHR/25/5731
Period of Framework Agreement: 1 September 2026 to 31 August 2028 with an option or option(s) to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
Lot 2 - Ustekinumab for North of England and Midlands & East, period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.
Commercial tool
Establishes a framework
Total value (estimated)
- £592,363,416 excluding VAT
- £710,836,100 including VAT
Above the relevant threshold
Contract dates (estimated)
- 1 September 2026 to 31 August 2028
- Possible extension to 31 August 2030
- 4 years
Main procurement category
Goods
CPV classifications
- 33600000 - Pharmaceutical products
Contract locations
- UKJ - South East (England)
- UKK - South West (England)
- UKI - London
- UKF - East Midlands (England)
- UKG - West Midlands (England)
- UKC - North East (England)
- UKD - North West (England)
Engagement
Engagement deadline
27 January 2026
Engagement process description
NHS England advises suppliers of an upcoming tender for the NHS Branded Medicines Agreement – Tranche B - Lot 1, scheduled to commence on 1 September 2026 for a 24-month term, with an option to extend for a further 24 months.
Lot 2 - Ustekinumab for North of England and Midlands & East, period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.
The purpose of this notice is to inform existing and potential suppliers that, where deemed beneficial, a virtual 1:1 preliminary market meeting can be arranged. Please contact Trushal.Patel@nhs.net to register your interest. A seven-day window for queries will be available via Atamis after all sessions have concluded.
This framework will cover six therapy areas including adalimumab, bevacizumab, cytokine modulators, interleukin inhibitors, JAK inhibitors, and monoclonal antibodies.
Participation
Particular suitability
Small and medium-sized enterprises (SME)
Submission
Publication date of tender notice (estimated)
23 February 2026
Contracting authority
NHS England
- Public Procurement Organisation Number: PDPT-3135-BWWY
Wellington House, 133-135 Waterloo Rd
London
SE1 8UG
United Kingdom
Region: UKI45 - Lambeth
Organisation type: Public authority - central government